APEC1621J: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF BVD-523FB (ULIXERTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIVATING MAPK PATHWAY MUTATIONS
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Patients With Tumors Harboring Activating Mapk Pathway Mutations
-
Age: Between 1 - 21 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) APEC1621SC: Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to MATCH to APEC1621J based on the presence of an actionable mutation. 2) Disease Status: Patients must have radiographically measurable disease at the time of study enrollment. Patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible. Measurable disease in patients with CNS involvement is defined as tumor that is measurable in two perpendicular diameters on MRI and visible on more than one slice.
You may not be eligible for this study if the following are true:
-
1) Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment and for 3 months after last dose of BVD-523FB (ulixertinib). 2) Infection: Patients who have an uncontrolled infection are not eligible. 3) Patients who have received a prior solid organ transplantation are not eligible.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.